Viela Bio Competitors

Dr. Reddy's Laboratories (NYSE:RDY) and Viela Bio (NASDAQ:VIE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Institutional & Insider Ownership

12.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 47.0% of Viela Bio shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Comparatively, 31.5% of Viela Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Dr. Reddy's Laboratories and Viela Bio, as reported by MarketBeat.

Dr. Reddy's Laboratories presently has a consensus target price of $70.00, indicating a potential upside of 1.89%. Viela Bio has a consensus target price of $57.00, indicating a potential upside of 7.53%. Given Viela Bio's higher probable upside, analysts plainly believe Viela Bio is more favorable than Dr. Reddy's Laboratories.

Profitability

This table compares Dr. Reddy's Laboratories and Viela Bio's net margins, return on equity and return on assets.

Volatility and Risk

Dr. Reddy's Laboratories has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Viela Bio has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.

Valuation and Earnings

This table compares Dr. Reddy's Laboratories and Viela Bio's revenue, earnings per share and valuation.

Dr. Reddy's Laboratories has higher revenue and earnings than Viela Bio. Viela Bio is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Summary

Dr. Reddy's Laboratories beats Viela Bio on 9 of the 14 factors compared between the two stocks.

Teva Pharmaceutical Industries (NYSE:TEVA) and Viela Bio (NASDAQ:VIE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Institutional & Insider Ownership

51.2% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 47.0% of Viela Bio shares are owned by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 31.5% of Viela Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Teva Pharmaceutical Industries and Viela Bio, as reported by MarketBeat.

Teva Pharmaceutical Industries presently has a consensus target price of $12.2222, indicating a potential upside of 19.83%. Viela Bio has a consensus target price of $57.00, indicating a potential upside of 7.53%. Given Teva Pharmaceutical Industries' higher probable upside, equities analysts plainly believe Teva Pharmaceutical Industries is more favorable than Viela Bio.

Profitability

This table compares Teva Pharmaceutical Industries and Viela Bio's net margins, return on equity and return on assets.

Volatility and Risk

Teva Pharmaceutical Industries has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, Viela Bio has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.

Valuation and Earnings

This table compares Teva Pharmaceutical Industries and Viela Bio's revenue, earnings per share and valuation.

Viela Bio has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Viela Bio is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Summary

Teva Pharmaceutical Industries beats Viela Bio on 9 of the 14 factors compared between the two stocks.

Bausch Health Companies (NYSE:BHC) and Viela Bio (NASDAQ:VIE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Valuation and Earnings

This table compares Bausch Health Companies and Viela Bio's revenue, earnings per share and valuation.

Viela Bio has lower revenue, but higher earnings than Bausch Health Companies. Viela Bio is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Bausch Health Companies and Viela Bio, as reported by MarketBeat.

Bausch Health Companies presently has a consensus target price of $32.5833, indicating a potential upside of 10.56%. Viela Bio has a consensus target price of $57.00, indicating a potential upside of 7.53%. Given Bausch Health Companies' stronger consensus rating and higher probable upside, equities analysts plainly believe Bausch Health Companies is more favorable than Viela Bio.

Profitability

This table compares Bausch Health Companies and Viela Bio's net margins, return on equity and return on assets.

Institutional & Insider Ownership

62.9% of Bausch Health Companies shares are owned by institutional investors. Comparatively, 47.0% of Viela Bio shares are owned by institutional investors. 12.1% of Bausch Health Companies shares are owned by insiders. Comparatively, 31.5% of Viela Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Bausch Health Companies has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Comparatively, Viela Bio has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.

Summary

Bausch Health Companies beats Viela Bio on 10 of the 14 factors compared between the two stocks.

Viela Bio (NASDAQ:VIE) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.

Valuation and Earnings

This table compares Viela Bio and Jazz Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Jazz Pharmaceuticals has higher revenue and earnings than Viela Bio. Viela Bio is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Viela Bio and Jazz Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Viela Bio and Jazz Pharmaceuticals, as provided by MarketBeat.

Viela Bio currently has a consensus price target of $57.00, indicating a potential upside of 7.53%. Jazz Pharmaceuticals has a consensus price target of $187.3684, indicating a potential upside of 11.95%. Given Jazz Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Viela Bio.

Institutional and Insider Ownership

47.0% of Viela Bio shares are owned by institutional investors. Comparatively, 95.7% of Jazz Pharmaceuticals shares are owned by institutional investors. 31.5% of Viela Bio shares are owned by company insiders. Comparatively, 4.6% of Jazz Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Viela Bio has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500.

Summary

Jazz Pharmaceuticals beats Viela Bio on 12 of the 14 factors compared between the two stocks.

United Therapeutics (NASDAQ:UTHR) and Viela Bio (NASDAQ:VIE) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Earnings and Valuation

This table compares United Therapeutics and Viela Bio's top-line revenue, earnings per share and valuation.

Viela Bio has lower revenue, but higher earnings than United Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than Viela Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares United Therapeutics and Viela Bio's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and price targets for United Therapeutics and Viela Bio, as provided by MarketBeat.com.

United Therapeutics presently has a consensus target price of $219.5714, suggesting a potential upside of 4.90%. Viela Bio has a consensus target price of $57.00, suggesting a potential upside of 7.53%. Given Viela Bio's higher possible upside, analysts plainly believe Viela Bio is more favorable than United Therapeutics.

Institutional and Insider Ownership

90.1% of United Therapeutics shares are held by institutional investors. Comparatively, 47.0% of Viela Bio shares are held by institutional investors. 10.9% of United Therapeutics shares are held by insiders. Comparatively, 31.5% of Viela Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

United Therapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500. Comparatively, Viela Bio has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500.

Summary

United Therapeutics beats Viela Bio on 10 of the 14 factors compared between the two stocks.

Maravai LifeSciences (NASDAQ:MRVI) and Viela Bio (NASDAQ:VIE) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Earnings and Valuation

This table compares Maravai LifeSciences and Viela Bio's top-line revenue, earnings per share and valuation.

Maravai LifeSciences has higher earnings, but lower revenue than Viela Bio.

Profitability

This table compares Maravai LifeSciences and Viela Bio's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and price targets for Maravai LifeSciences and Viela Bio, as provided by MarketBeat.com.

Maravai LifeSciences presently has a consensus target price of $38.1250, suggesting a potential upside of 6.20%. Viela Bio has a consensus target price of $57.00, suggesting a potential upside of 7.53%. Given Viela Bio's higher possible upside, analysts plainly believe Viela Bio is more favorable than Maravai LifeSciences.

Institutional and Insider Ownership

47.0% of Viela Bio shares are held by institutional investors. 31.5% of Viela Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.